<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875626</url>
  </required_header>
  <id_info>
    <org_study_id>FLUOBREAST</org_study_id>
    <nct_id>NCT02875626</nct_id>
  </id_info>
  <brief_title>Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer</brief_title>
  <official_title>Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer (FLUO-BREAST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center prospective study evaluating the diagnostic performance and safety of&#xD;
      Infracyanine in women with early breast cancer whose the research of sentinel node(s)&#xD;
      combines isotopes and Infracyanine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visits:&#xD;
&#xD;
      Screening:&#xD;
&#xD;
      Complete physical and gynecological examination by surgical oncologist Informed and signed&#xD;
      consent form. The intervention will be planned within one month.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      In the beginning of the intervention, a periareolar injection of the Infracyanine will be&#xD;
      carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).&#xD;
&#xD;
      The search or sentinel node will be made using a infrared camera for transcutaneous&#xD;
      visualization Secondly, data lymphoscintigraphy may be communicated to the surgeon. The nodes&#xD;
      are identified as SN fluorescent nodes and / or radioactive nodes.&#xD;
&#xD;
        -  All radioactive nodes and / or fluorescent will be deleted&#xD;
&#xD;
        -  Reports of anatomy fluorescent SN and / or hot&#xD;
&#xD;
      Next visit:&#xD;
&#xD;
      The patient will be reviewed in consultation in the months following the itervention for a&#xD;
      clinical examination, the collection of adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the SN detection rate during surgery by fluorescence, by isotopes, by combining the two. The detection rate is defined by the number of patient</measure>
    <time_frame>During surgery</time_frame>
    <description>The detection rate is defined by the number of patient who at least one axillary sentinel node detected by fluorescence and / or isotope intraoperatively / number of female patients injected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time between the incision and removal of the first sentinel node identified</measure>
    <time_frame>During surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The sensitivity of indocyanine green compared to the technical reference ( percentage of nodes detected by the isotope and which are also detected by the indocyanine green )</measure>
    <time_frame>During surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The wrong negative rate (number of female patients in whom at least one metastatic sentinel node has been detected by isotope and not by ICG)</measure>
    <time_frame>During surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical direct cost</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rates of allergic reactions</measure>
    <time_frame>From screening till 1 month after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of allergic reactions (grade 1 to 5 according to Ring and al 38 )</measure>
    <time_frame>From screening till 1 month after the surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Infracyanine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infracyanine</intervention_name>
    <description>In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).</description>
    <arm_group_label>Infracyanine</arm_group_label>
    <other_name>indocyanin green</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female age &gt; 18 years&#xD;
&#xD;
          2. Invasive breast cancer ≤ 5 cm, unifocal bifocal or multifocal&#xD;
&#xD;
          3. Diagnosis confirmed by biopsy&#xD;
&#xD;
          4. Breast cancer extended in situ&#xD;
&#xD;
          5. First surgical treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neoadjuvant chemotherapy or hormone therapy.&#xD;
&#xD;
          2. Multicentric tumor&#xD;
&#xD;
          3. Pregnant patient&#xD;
&#xD;
          4. Ongoing participation in another clinical trial with an investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte NGO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

